UC San Francisco scientists have discovered a new way to control the immune system’s “natural killer” (NK) cells, a finding with implications for novel cell therapies and tissue implants that can evade immune rejection. The findings could also be used to enhance the ability of cancer immunotherapies to detect and destroy lurking tumors.
The study, published today (January 8, 2021) in the Journal of Experimental Medicine, addresses a major challenge for the field of regenerative medicine, said lead author Tobias Deuse, MD, the Julien I.E. Hoffman, MD, Endowed Chair in Cardiac Surgery in the UCSF Department of Surgery.
“As a cardiac surgeon, I would love to put myself out of business by being able to implant healthy cardiac cells to repair heart disease,” said Deuse, who is interim chair and director of minimally invasive cardiac surgery in the Division of Adult Cardiothoracic Surgery. “And there are tremendous hopes to one day have the ability to implant insulin-producing cells in patients with diabetes or to inject cancer patients with immune cells engineered to seek and destroy tumors. The major obstacle is how to do this in a way that avoids immediate rejection by the immune system.”
Deuse and Sonja Schrepfer, MD, PhD, also a professor in the Department of Surgery’s Transplant and Stem Cell Immunobiology Laboratory, study the immunobiology of stem cells. They are world leaders in a growing scientific subfield working to produce “hypoimmune” lab-grown cells and tissues — capable of evading detection and rejection by the immune system. One of the key methods for doing this is to engineer cells with molecular passcodes that activate immune cell “off switches” called immune checkpoints, which normally help prevent the immune system from attacking the body’s own cells and modulate the intensity of immune responses to avoid excess collateral damage.
Schrepfer and Deuse recently used gene modification tools to engineer hypoimmune stem cells in the lab that are effectively invisible to the immune system. Notably, as well as avoiding the body’s learned or “adaptive” immune responses, these cells could also evade the body’s automatic “innate” immune response against potential pathogens. To achieve this, the researchers adapted a strategy used by cancer cells to keep innate immune cells at bay: They engineered their cells to express significant levels of a protein called CD47, which shuts down certain innate immune cells by activating a molecular switch found on these cells, called SIRPα. Their success became part of the founding technology of Sana Biotechnology, Inc, a company co-founded by Schrepfer, who now directs a team developing a platform based on these hypoimmune cells for clinical use.
But the researchers were left with a mystery on their hands — the technique was more successful than predicted. In particular, the field was puzzled that such engineered hypoimmune cells were able to deftly evade detection by NK cells, a type of innate immune cell that isn’t supposed to express a SIRPα checkpoint at all.
NK cells are a type of white blood cell that acts as an immunological first responder, quickly detecting and destroying any cells without proper molecular ID proving they are “self” — native body cells or at least permanent residents — which takes the form of highly individualized molecules called MHC class I (MHC-I). When MHC-I is artificially knocked out to prevent transplant rejection, the cells become susceptible to accelerated NK cell killing, an immunological rejection that no one in the field had yet succeeded in inhibiting fully. Deuse and Schrepfer’s 2019 data, published in Nature Biotechnology, suggested they might have stumbled upon an off switch that could be used for that purpose.
“All the literature said that NK cells don’t have this checkpoint, but when we looked at cells from human patients in the lab we found SIRPα there, clear as day,” Schrepfer recalled. “We can clearly demonstrate that stem cells we engineer to overexpress CD47 are able to shut down NK cells through this pathway.”
To explore their data, Deuse and Schrepfer approached Lewis Lanier, PhD, a world expert in NK cell biology. At first Lanier was sure there must be some mistake, because several groups had looked for SIRPα in NK cells already and it wasn’t there. But Schrepfer was confident in her team’s data.
Image Credit: UC San Francisco
Post by Amanda Scott, NA CEO. Follow her on twitter @tantriclens
Thanks to Heinz V. Hoenen. Follow him on twitter: @HeinzVHoenen

News
A potential milestone in cancer therapy
Researchers from the University of Bern, Inselspital, University Hospital Bern, and the University of Connecticut have made a significant breakthrough in the fight against cancer. They identified a previously unknown weak point of prostate [...]
Cardiovascular Crystal Ball: New Tool Predicts Future Heart Disease Risk
Faculty members at the UM School of Medicine have created a cutting-edge tool that enables the early identification and assessment of risks in vulnerable patients. Heart disease, being the leading cause of death globally, [...]
Scientists analyze a single atom with X-rays for the first time
In the most powerful X-ray facilities in the world, scientists can analyze samples so small they contain only 10,000 atoms. Smaller sizes have proved exceedingly difficult to achieve, but a multi-institutional team has scaled [...]
AI Demonstrates Superior Performance in Predicting Breast Cancer
AI algorithms outperformed traditional clinical risk models in a large-scale study, predicting five-year breast cancer risk more accurately. These models use mammograms as the single data source, offering potential advantages in individualizing patient care [...]
Stanford Medicine Reveals: Tiny DNA Circles Defying Genetic Laws Drive Cancer Formation
Tiny circles of DNA harbor cancer-associated oncogenes and immunomodulatory genes promoting cancer development. They arise during the transformation from pre-cancer to cancer, say Stanford Medicine-led team. Tiny circles of DNA that defy the accepted laws of [...]
Death to Blood Cancer Cells: New Drug Combination Could Revive the Power of Leading Treatment
Future clinical trials will be conducted to investigate whether the combination of chloroquine and venetoclax can prevent disease recurrence. Although new drugs have been developed to induce cancer cell death in individuals with acute [...]
Illuminating Science: X-Rays Visualize How One of Nature’s Strongest Bonds Breaks
Scientists have deciphered how an activated catalyst breaks down the strong carbon-hydrogen bonds in potent greenhouse gas methane, according to a study published in Science. Using advanced X-ray technology and quantum-chemical calculations, they tracked the [...]
Using magnetic nanoparticles as a rapid test for sepsis
Qun Ren, an Empa researcher, and her team are currently developing a diagnostic procedure that can rapidly detect life-threatening blood poisoning caused by staphylococcus bacteria. Staphylococcal sepsis is fatal in up to 40% of [...]
Team develops nanoparticles to deliver brain cancer treatment
University of Queensland researchers have developed a nanoparticle to take a chemotherapy drug into fast growing, aggressive brain tumors. Research team lead Dr. Taskeen Janjua from UQ's School of Pharmacy said the new silica [...]
Tumor Avatars – A New Approach to Personalized Cancer Treatment
A team from the University of Geneva (UNIGE) has devised a novel method for customizing treatments by testing them on artificial tumors. Determining the optimal treatment for colon cancer can be challenging as each [...]
STING Like a Bee: MIT’s Revolutionary Approach to Cancer Immunotherapy
A cancer vaccine combining checkpoint blockade therapy and a STING-activating drug eliminates tumors and prevents recurrence in mice. MIT researchers have engineered a therapeutic cancer vaccine that targets the STING pathway, vital for immune response [...]
AI Battles Superbugs: Helps Find New Antibiotic Drug To Combat Drug-Resistant Infections
The machine-learning algorithm identified a compound that kills Acinetobacter baumannii, a bacterium that lurks in many hospital settings. Using an artificial intelligence algorithm, researchers at MIT and McMaster University have identified a new antibiotic that can kill a [...]
Cancer and AI – Can ChatGPT Be Trusted?
A study published in the Journal of The National Cancer Institute Cancer Spectrum delved into the increasing use of chatbots and artificial intelligence (AI) in providing cancer-related information. The researchers discovered that these digital resources accurately [...]
Breathing New Life: Oxygen Therapy Improves Heart Function in Long COVID Patients
A small trial has found that hyperbaric oxygen therapy (HBOT) may help restore proper heart function in patients with post-COVID syndrome, with participants in the HBOT group experiencing a significant increase in global longitudinal [...]
Wireless Brain-Spine Interface: A Leap Towards Reversing Paralysis
Summary: In a pioneering study, researchers designed a wireless brain-spine interface enabling a paralyzed man to walk naturally again. The ‘digital bridge’ comprises two electronic implants — one on the brain and another on the [...]
New study reveals a gel that promises to wipe out brain cancer for good
An anti-cancer gel promises to wipe out glioblastoma permanently, a feat that's never been accomplished by any drug or surgery. So what makes this gel so special? Scientists at Johns Hopkins University (JHU) have [...]